Morgan Stanley Sticks to Their Buy Rating for Pro Medicus Limited (PMCUF)
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 13 2025
0mins
Should l Buy ?
Source: Business Insider
Analyst Ratings: Morgan Stanley's Chris Boulus maintains a Buy rating on Pro Medicus Limited with a price target of A$310.00, while Goldman Sachs also holds a Buy rating at A$309.00; however, the overall analyst consensus is a Hold with a lower price target of $163.80.
Company Performance: Pro Medicus reported strong financial growth for the quarter ending June 30, with revenues increasing to $87.39 million and net profits rising to $46.54 million compared to the previous year, despite negative insider sentiment regarding stock sales.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
